Pulmonary hypertension: pathophysiology, diagnosis, treatment, and development of a pulmonary selective therapy
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Language: | English |
| Published: |
Bremen [u.a.]
UNI-MED-Verl.
2002
|
| Edition: | 1. Aufl. |
| Series: | UNI-MED science
|
| Subjects: | |
| Online Access: | Inhaltsverzeichnis |
| Item Description: | Literaturverz. S. 114 - 131 |
| Physical Description: | 136 S. Ill., graph. Darst 25 cm |
| ISBN: | 3895995940 |
Staff View
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV022193243 | ||
| 003 | DE-604 | ||
| 005 | 20210625 | ||
| 007 | t | ||
| 008 | 061214s2002 gw ad|| |||| 00||| eng d | ||
| 016 | 7 | |a 963735519 |2 DE-101 | |
| 020 | |a 3895995940 |c Pp. : EUR 44.80, sfr 79.20 |9 3-89599-594-0 | ||
| 035 | |a (OCoLC)49385779 | ||
| 035 | |a (DE-599)BVBBV022193243 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c DE | ||
| 049 | |a DE-20 |a DE-384 | ||
| 084 | |a YB 1503 |0 (DE-625)153103:12909 |2 rvk | ||
| 084 | |a YB 6738 |0 (DE-625)153151:12945 |2 rvk | ||
| 100 | 1 | |a Olschewski, Horst |e Verfasser |4 aut | |
| 240 | 1 | 0 | |a Pulmonale Hypertonie |
| 245 | 1 | 0 | |a Pulmonary hypertension |b pathophysiology, diagnosis, treatment, and development of a pulmonary selective therapy |c Horst Olschewski ; Werner Seeger |
| 250 | |a 1. Aufl. | ||
| 264 | 1 | |a Bremen [u.a.] |b UNI-MED-Verl. |c 2002 | |
| 300 | |a 136 S. |b Ill., graph. Darst |c 25 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a UNI-MED science | |
| 500 | |a Literaturverz. S. 114 - 131 | ||
| 650 | 4 | |a Hypertension, Pulmonary |x diagnosis | |
| 650 | 4 | |a Hypertension, Pulmonary |x physiopathology | |
| 650 | 4 | |a Hypertension, Pulmonary |x therapy | |
| 650 | 4 | |a Vasodilator Agents |x therapeutic use | |
| 650 | 0 | 7 | |a Pulmonale Hypertonie |0 (DE-588)4176331-2 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Pulmonale Hypertonie |0 (DE-588)4176331-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Seeger, Werner |d 1953- |e Verfasser |0 (DE-588)140597085 |4 aut | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015404785&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-015404785 | ||
Record in the Search Index
| _version_ | 1804136166964854784 |
|---|---|
| adam_text | Contents 7
Contents
^| Introduction 12
^J Physiology of the Pulmonary Circulation 16
2.1. Special Features of the Pulmonary Circulation 16
2.2. Vasoconstrictive and Vasodilatory Mechanisms 17
2.2.1. Second Messengers 19
2.2.2. Potassium Channels 19
2.2.3. Mediators of Pulmonary Vascular Tone 20
2.2.3.1. Catecholamines 21
2.2.3.2. Nitric Oxide (NO), Previously EDRF 21
2.2.3.3. Prostacyclin (PGI2) 21
2.2.3.4. Endothelin 22
2.2.3.5. Natriuretic Peptides (ANP and BNP) 22
2.2.4. Vasoconstrictive Mechanisms of the Pulmonary Circulation 23
2.2.4.1. Hypoxic Pulmonary Vasoconstriction 23
2.2.4.2. Pulmonary Venous Pressure Increase 25
m Pathophysiology 28
3.1. The Causes of Pulmonary Hypertension 28
3.2. Assessing Pulmonary Hypertension 28
3.3. Right Ventricular Adaptation 30
3.4. Remodeling, Vasoconstriction and In Situ Thrombosis in the Pulmonary Arteries 30
3.4.1. Remodeling 30
3.4.2. Vasoconstriction 32
3.4.3. Thrombosis 32
3.5. Mediator Imbalance 33
3.5.1. Increased Endothelin Levels 34
3.5.2. Reduced Prostacyclin/ Thromboxane Ratio 34
3.5.3. Increased Serotonin Levels 35
3.5.4. Elevated Levels of Proinflammatory Lipid Mediators 35
3.5.5. Prevalence of Prothrombotic Factors 35
3.6. Feedback Mechanisms 35
3.6.1. Vicious Circles in Pulmonary Hypertension 35
3.6.1.1. Mechanical Stress 35
3.6.1.2. Polycythemia 36
3.6.1.3. In Situ Thrombosis 36
3.6.1.4. Changes in Gene Expression 36
3.6.2. Negative Feedback 37
3.6.2.1. NO 37
3.6.2.2. Increased ANP Levels 37
|H Diagnosis and Classification According to the WHO World Conference on
PPHinEvian(1998) 40
4.1. Risk Factors and Associated Conditions 40
4.2. Nomenclature and Classification of Pulmonary Hypertension 41
4.2.1. Diagnostic Classification 41
4.2.2. Functional Assessment 43
8 Contents
4.3. Diagnosis of Pulmonary Hypertension (Recommendations of the Evian Symposium) 43
4.3.1. Screening for Pulmonary Hypertension 44
4.3.1.1. Connective Tissue Diseases 44
4.3.1.2. Families of Documented PPH 44
4.3.1.3. Liver Disease/Portal Hypertension 44
4.3.1.4. HIV Infection 44
4.3.1.5. Patients with a History of Intravenous Drug Use 44
4.3.1.6. Patients with a History of Appetite Suppressant Drug Use 45
4.3.1.7. The Evaluation of mild Pulmonary Hypertension 45
4.3.1.8. Asymptomatic Individuals (Incidental Discovery) 45
4.3.1.9. Symptomatic Individuals 45
4.3.1.10. High Risk Individuals 45
4.3.2. Medical Testing to Characterize Pulmonary Hypertension 45
4.4. Our Suggestions for a Practical Approach 46
4.4.1. Diagnosis of Suspected Pulmonary Hypertension 46
4.4.2. Differential Diagnosis of Pulmonary Hypertension 48
4.4.3. Functional Assessment of the Severity of Pulmonary Hypertension 50
HI Specific Clinical Syndromes 52
5.1. Primary Pulmonary Hypertension (PPH) 52
5.1.1. Epidemiology 52
5.1.2. Pathogenesis 52
5.1.3. Catalogue of Symptoms 52
5.1.4. Physical Examination 53
5.1.5. Technical Examinations 54
5.2. Familial PPH 59
5.3. Further Diseases Belonging to the Category Pulmonary Arterial Hypertension 60
5.3.1. Connective Tissue Diseases 60
5.3.2. Congenital Systemic to Pulmonary Shunt Defects 60
5.3.3. Portal Hypertension 61
5.3.3.1. Hepatopulmonary Syndrome 62
5.3.3.2. Portopulmonary Hypertension 62
5.3.4. HIV Infection 63
5.3.5. Drugs/Toxins 64
5.3.5.1. Anorectics 64
5.3.5.2. Amphetamines 64
5.3.5.3. Toxic Oil Syndrome 64
5.3.5.4. Further Possible Triggers 65
5.4. Pulmonary Venous Hypertension 65
5.4.1. Left sided Myocardial or Valvular Disease 65
5.4.2. Extrinsic Compression of the Pulmonary Veins 66
5.4.3. Veno Occlusive Disease 66
5.5. Pulmonary Hypertension in Association with Respiratory Diseases and/or Hypoxia 68
5.5.1. Structural Vessel Loss 68
5.5.2. Hypoxia 68
5.5.2.1. High Altitude Lung Oedema 69
5.5.3. Inflammation 69
5.6. Pulmonary Hypertension Following Chronic Thrombotic and/or Embolic Diseases 70
5.6.1. Chronic Thromboembolic Pulmonary Hypertension 70
5.6.2. Chronic Microembolism/Thrombosis 71
Contents 9
5.7. Pulmonary Hypertension Following Diseases that Directly Affect the Pulmonary Vessels ... 71
5.7.1. Inflammatory Diseases 71
5.7.1.1. Schistosomiasis 71
5.7.1.2. Sarcoidosis 71
5.7.1.3. Behcet s Disease 71
5.7.2. Pulmonary Capillary Hemangiomatosis 72
^| The Therapy of Severe Pulmonary Hypertension 74
6.1. Treatment 74
6.1.1. Muscle Conditioning in Spite of Physical Limitations 74
6.1.2. Anticoagulation 74
6.1.3. Long term Therapy with O2 75
6.1.4. Therapy for Infection 75
6.1.5. Venesection/Diuretics 75
6.2. Specific Diseases 75
6.2.1. HIV Infection 75
6.2.2. Left to Right Shunt Defects 75
6.2.3. Chronic Pulmonary Embolism 76
6.2.4. Pulmonary Disease and Chronic Hypoxia 77
6.2.5. Interstitial Pulmonary Disease 77
6.2.6. Thrombocytic Diseases 77
6.3. Systemic Vasodilators 77
6.3.1. Dihydralazine 77
6.3.2. Calcium Channel Blockers 78
6.3.3. Adenosine 79
6.4. Prostacyclin 79
6.4.1. The Development of this Therapy 79
6.4.2. Pathophysiological Background 80
6.4.3. Practical Application 80
6.4.4. Problems with Intravenous Prostacyclin 80
6.4.5. Alternative Approaches using Prostanoids 81
6.5. Other Medical Approaches 81
6.5.1. Endothelin Antagonists 81
6.5.2. PDE Inhibitors 82
6.5.3. Thromboxane Antagonists 82
6.5.4. ACE Antagonists 83
6.5.5. Atrial Natriuretic Peptide (ANP) 83
6.5.6. Heparin 83
6.5.7. Potassium Channel Agonists 83
6.5.8. Other Pharmacological Agents 84
6.6. Gene Therapy 84
6.7. Lung Transplantation 84
6.8. Atrial Septostomy 85
6.9. Suggestions for the Therapy of Pulmonary Arterial Hypertension 85
6.9.1. Starting Specific Therapy for NO Responders 86
6.9.2. Starting Therapy for NO Nonresponders 86
10 Contents
^| Inhaled Vasodilators as a New Concept for Therapy of Severe Pulmonary
Hypertension 90
7.1. Background 90
7.1.1. Is Continuous Infusion Necessary? 90
7.1.2. Inhaled Administration 90
7.2. Pulmonary Selective Vasodilatation 90
7.2.1. NO 90
7.2.2. Problems Using Inhaled NO 91
7.2.2.1. Toxicology 91
7.2.2.2. Rebound Phenomenon 91
7.2.2.3. Nonresponders 92
7.2.3. Inhaled Prostanoids 92
7.2.3.1. First Description of Inhaled Application of Prostacyclin on Patients with ARDS 92
7.2.3.2. First Description of Use in PPH 92
7.3. The Effects of Inhaled Prostacyclin and lloprost in PPH and Isolated and Secondary
Pulmonary Hypertension 93
7.3.1. Assessment of the hemodynamic profile 93
7.3.1.1. A Comparison of the Hemodynamic Effects of Inhaled NO and Inhaled lloprost in PPH 94
7.3.1.2. Inhaled Prostacyclin in Interstitial Lung Disease 96
7.3.1.3. The Effects of Prostanoids on Gas Exchange in Chronic Thromboembolic Pulmonary Hypertension 96
7.3.2. Long term Therapy with Inhaled lloprost 97
7.3.2.1. Use of Inhaled lloprost in Decompensated Pulmonary Hypertension 97
7.3.2.2. Experience with Long term Aerosolised lloprost Therapy 101
7.3.2.3. Trials Concerning Approval of Inhaled lloprost 103
7.4. Aerosolisation Technology 103
7.5. Drawbacks of Inhaled lloprost 105
7.5.1. Toxicology 105
7.5.2. Inhalation Intervals 105
7.5.3. Therapy Costs 106
7.6. Ethical Aspects 106
7.7. Inhaled lloprost in Combination with Other Medical Approaches 107
^| Summary 110
m References 114
[H Index 133
|
| adam_txt |
Contents 7
Contents
^| Introduction 12
^J Physiology of the Pulmonary Circulation 16
2.1. Special Features of the Pulmonary Circulation 16
2.2. Vasoconstrictive and Vasodilatory Mechanisms 17
2.2.1. Second Messengers 19
2.2.2. Potassium Channels 19
2.2.3. Mediators of Pulmonary Vascular Tone 20
2.2.3.1. Catecholamines 21
2.2.3.2. Nitric Oxide (NO), Previously EDRF 21
2.2.3.3. Prostacyclin (PGI2) 21
2.2.3.4. Endothelin 22
2.2.3.5. Natriuretic Peptides (ANP and BNP) 22
2.2.4. Vasoconstrictive Mechanisms of the Pulmonary Circulation 23
2.2.4.1. Hypoxic Pulmonary Vasoconstriction 23
2.2.4.2. Pulmonary Venous Pressure Increase 25
m Pathophysiology 28
3.1. The Causes of Pulmonary Hypertension 28
3.2. Assessing Pulmonary Hypertension 28
3.3. Right Ventricular Adaptation 30
3.4. Remodeling, Vasoconstriction and In Situ Thrombosis in the Pulmonary Arteries 30
3.4.1. Remodeling 30
3.4.2. Vasoconstriction 32
3.4.3. Thrombosis 32
3.5. Mediator Imbalance 33
3.5.1. Increased Endothelin Levels 34
3.5.2. Reduced Prostacyclin/ Thromboxane Ratio 34
3.5.3. Increased Serotonin Levels 35
3.5.4. Elevated Levels of Proinflammatory Lipid Mediators 35
3.5.5. Prevalence of Prothrombotic Factors 35
3.6. Feedback Mechanisms 35
3.6.1. Vicious Circles in Pulmonary Hypertension 35
3.6.1.1. Mechanical Stress 35
3.6.1.2. Polycythemia 36
3.6.1.3. In Situ Thrombosis 36
3.6.1.4. Changes in Gene Expression 36
3.6.2. Negative Feedback 37
3.6.2.1. NO 37
3.6.2.2. Increased ANP Levels 37
|H Diagnosis and Classification According to the WHO World Conference on
PPHinEvian(1998) 40
4.1. Risk Factors and Associated Conditions 40
4.2. Nomenclature and Classification of Pulmonary Hypertension 41
4.2.1. Diagnostic Classification 41
4.2.2. Functional Assessment 43
8 Contents
4.3. Diagnosis of Pulmonary Hypertension (Recommendations of the Evian Symposium) 43
4.3.1. Screening for Pulmonary Hypertension 44
4.3.1.1. Connective Tissue Diseases 44
4.3.1.2. Families of Documented PPH 44
4.3.1.3. Liver Disease/Portal Hypertension 44
4.3.1.4. HIV Infection 44
4.3.1.5. Patients with a History of Intravenous Drug Use 44
4.3.1.6. Patients with a History of Appetite Suppressant Drug Use 45
4.3.1.7. The Evaluation of mild Pulmonary Hypertension 45
4.3.1.8. Asymptomatic Individuals (Incidental Discovery) 45
4.3.1.9. Symptomatic Individuals 45
4.3.1.10. High Risk Individuals 45
4.3.2. Medical Testing to Characterize Pulmonary Hypertension 45
4.4. Our Suggestions for a Practical Approach 46
4.4.1. Diagnosis of Suspected Pulmonary Hypertension 46
4.4.2. Differential Diagnosis of Pulmonary Hypertension 48
4.4.3. Functional Assessment of the Severity of Pulmonary Hypertension 50
HI Specific Clinical Syndromes 52
5.1. Primary Pulmonary Hypertension (PPH) 52
5.1.1. Epidemiology 52
5.1.2. Pathogenesis 52
5.1.3. Catalogue of Symptoms 52
5.1.4. Physical Examination 53
5.1.5. Technical Examinations 54
5.2. Familial PPH 59
5.3. Further Diseases Belonging to the Category "Pulmonary Arterial Hypertension" 60
5.3.1. Connective Tissue Diseases 60
5.3.2. Congenital Systemic to Pulmonary Shunt Defects 60
5.3.3. Portal Hypertension 61
5.3.3.1. Hepatopulmonary Syndrome 62
5.3.3.2. Portopulmonary Hypertension 62
5.3.4. HIV Infection 63
5.3.5. Drugs/Toxins 64
5.3.5.1. Anorectics 64
5.3.5.2. Amphetamines 64
5.3.5.3. Toxic Oil Syndrome 64
5.3.5.4. Further Possible Triggers 65
5.4. Pulmonary Venous Hypertension 65
5.4.1. Left sided Myocardial or Valvular Disease 65
5.4.2. Extrinsic Compression of the Pulmonary Veins 66
5.4.3. Veno Occlusive Disease 66
5.5. Pulmonary Hypertension in Association with Respiratory Diseases and/or Hypoxia 68
5.5.1. Structural Vessel Loss 68
5.5.2. Hypoxia 68
5.5.2.1. High Altitude Lung Oedema 69
5.5.3. Inflammation 69
5.6. Pulmonary Hypertension Following Chronic Thrombotic and/or Embolic Diseases 70
5.6.1. Chronic Thromboembolic Pulmonary Hypertension 70
5.6.2. Chronic Microembolism/Thrombosis 71
Contents 9
5.7. Pulmonary Hypertension Following Diseases that Directly Affect the Pulmonary Vessels . 71
5.7.1. Inflammatory Diseases 71
5.7.1.1. Schistosomiasis 71
5.7.1.2. Sarcoidosis 71
5.7.1.3. Behcet's Disease 71
5.7.2. Pulmonary Capillary Hemangiomatosis 72
^| The Therapy of Severe Pulmonary Hypertension 74
6.1. Treatment 74
6.1.1. Muscle Conditioning in Spite of Physical Limitations 74
6.1.2. Anticoagulation 74
6.1.3. Long term Therapy with O2 75
6.1.4. Therapy for Infection 75
6.1.5. Venesection/Diuretics 75
6.2. Specific Diseases 75
6.2.1. HIV Infection 75
6.2.2. Left to Right Shunt Defects 75
6.2.3. Chronic Pulmonary Embolism 76
6.2.4. Pulmonary Disease and Chronic Hypoxia 77
6.2.5. Interstitial Pulmonary Disease 77
6.2.6. Thrombocytic Diseases 77
6.3. Systemic Vasodilators 77
6.3.1. Dihydralazine 77
6.3.2. Calcium Channel Blockers 78
6.3.3. Adenosine 79
6.4. Prostacyclin 79
6.4.1. The Development of this Therapy 79
6.4.2. Pathophysiological Background 80
6.4.3. Practical Application 80
6.4.4. Problems with Intravenous Prostacyclin 80
6.4.5. Alternative Approaches using Prostanoids 81
6.5. Other Medical Approaches 81
6.5.1. Endothelin Antagonists 81
6.5.2. PDE Inhibitors 82
6.5.3. Thromboxane Antagonists 82
6.5.4. ACE Antagonists 83
6.5.5. Atrial Natriuretic Peptide (ANP) 83
6.5.6. Heparin 83
6.5.7. Potassium Channel Agonists 83
6.5.8. Other Pharmacological Agents 84
6.6. Gene Therapy 84
6.7. Lung Transplantation 84
6.8. Atrial Septostomy 85
6.9. Suggestions for the Therapy of Pulmonary Arterial Hypertension 85
6.9.1. Starting Specific Therapy for NO Responders 86
6.9.2. Starting Therapy for NO Nonresponders 86
10 Contents
^| Inhaled Vasodilators as a New Concept for Therapy of Severe Pulmonary
Hypertension 90
7.1. Background 90
7.1.1. Is Continuous Infusion Necessary? 90
7.1.2. Inhaled Administration 90
7.2. Pulmonary Selective Vasodilatation 90
7.2.1. NO 90
7.2.2. Problems Using Inhaled NO 91
7.2.2.1. Toxicology 91
7.2.2.2. Rebound Phenomenon 91
7.2.2.3. Nonresponders 92
7.2.3. Inhaled Prostanoids 92
7.2.3.1. First Description of Inhaled Application of Prostacyclin on Patients with ARDS 92
7.2.3.2. First Description of Use in PPH 92
7.3. The Effects of Inhaled Prostacyclin and lloprost in PPH and Isolated and Secondary
Pulmonary Hypertension 93
7.3.1. Assessment of the hemodynamic profile 93
7.3.1.1. A Comparison of the Hemodynamic Effects of Inhaled NO and Inhaled lloprost in PPH 94
7.3.1.2. Inhaled Prostacyclin in Interstitial Lung Disease 96
7.3.1.3. The Effects of Prostanoids on Gas Exchange in Chronic Thromboembolic Pulmonary Hypertension 96
7.3.2. Long term Therapy with Inhaled lloprost 97
7.3.2.1. Use of Inhaled lloprost in Decompensated Pulmonary Hypertension 97
7.3.2.2. Experience with Long term Aerosolised lloprost Therapy 101
7.3.2.3. Trials Concerning Approval of Inhaled lloprost 103
7.4. Aerosolisation Technology 103
7.5. Drawbacks of Inhaled lloprost 105
7.5.1. Toxicology 105
7.5.2. Inhalation Intervals 105
7.5.3. Therapy Costs 106
7.6. Ethical Aspects 106
7.7. Inhaled lloprost in Combination with Other Medical Approaches 107
^| Summary 110
m References 114
[H Index 133 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Olschewski, Horst Seeger, Werner 1953- |
| author_GND | (DE-588)140597085 |
| author_facet | Olschewski, Horst Seeger, Werner 1953- |
| author_role | aut aut |
| author_sort | Olschewski, Horst |
| author_variant | h o ho w s ws |
| building | Verbundindex |
| bvnumber | BV022193243 |
| classification_rvk | YB 1503 YB 6738 |
| ctrlnum | (OCoLC)49385779 (DE-599)BVBBV022193243 |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| edition | 1. Aufl. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01826nam a2200457 c 4500</leader><controlfield tag="001">BV022193243</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20210625 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">061214s2002 gw ad|| |||| 00||| eng d</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">963735519</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3895995940</subfield><subfield code="c">Pp. : EUR 44.80, sfr 79.20</subfield><subfield code="9">3-89599-594-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)49385779</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV022193243</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">DE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-20</subfield><subfield code="a">DE-384</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YB 1503</subfield><subfield code="0">(DE-625)153103:12909</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YB 6738</subfield><subfield code="0">(DE-625)153151:12945</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Olschewski, Horst</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="240" ind1="1" ind2="0"><subfield code="a">Pulmonale Hypertonie</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pulmonary hypertension</subfield><subfield code="b">pathophysiology, diagnosis, treatment, and development of a pulmonary selective therapy</subfield><subfield code="c">Horst Olschewski ; Werner Seeger</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1. Aufl.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bremen [u.a.]</subfield><subfield code="b">UNI-MED-Verl.</subfield><subfield code="c">2002</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">136 S.</subfield><subfield code="b">Ill., graph. Darst</subfield><subfield code="c">25 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">UNI-MED science</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Literaturverz. S. 114 - 131</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hypertension, Pulmonary</subfield><subfield code="x">diagnosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hypertension, Pulmonary</subfield><subfield code="x">physiopathology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hypertension, Pulmonary</subfield><subfield code="x">therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vasodilator Agents</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pulmonale Hypertonie</subfield><subfield code="0">(DE-588)4176331-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Pulmonale Hypertonie</subfield><subfield code="0">(DE-588)4176331-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Seeger, Werner</subfield><subfield code="d">1953-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)140597085</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015404785&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-015404785</subfield></datafield></record></collection> |
| id | DE-604.BV022193243 |
| illustrated | Illustrated |
| index_date | 2024-07-02T16:22:01Z |
| indexdate | 2024-07-09T20:52:05Z |
| institution | BVB |
| isbn | 3895995940 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-015404785 |
| oclc_num | 49385779 |
| open_access_boolean | |
| owner | DE-20 DE-384 |
| owner_facet | DE-20 DE-384 |
| physical | 136 S. Ill., graph. Darst 25 cm |
| publishDate | 2002 |
| publishDateSearch | 2002 |
| publishDateSort | 2002 |
| publisher | UNI-MED-Verl. |
| record_format | marc |
| series2 | UNI-MED science |
| spelling | Olschewski, Horst Verfasser aut Pulmonale Hypertonie Pulmonary hypertension pathophysiology, diagnosis, treatment, and development of a pulmonary selective therapy Horst Olschewski ; Werner Seeger 1. Aufl. Bremen [u.a.] UNI-MED-Verl. 2002 136 S. Ill., graph. Darst 25 cm txt rdacontent n rdamedia nc rdacarrier UNI-MED science Literaturverz. S. 114 - 131 Hypertension, Pulmonary diagnosis Hypertension, Pulmonary physiopathology Hypertension, Pulmonary therapy Vasodilator Agents therapeutic use Pulmonale Hypertonie (DE-588)4176331-2 gnd rswk-swf Pulmonale Hypertonie (DE-588)4176331-2 s DE-604 Seeger, Werner 1953- Verfasser (DE-588)140597085 aut HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015404785&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Olschewski, Horst Seeger, Werner 1953- Pulmonary hypertension pathophysiology, diagnosis, treatment, and development of a pulmonary selective therapy Hypertension, Pulmonary diagnosis Hypertension, Pulmonary physiopathology Hypertension, Pulmonary therapy Vasodilator Agents therapeutic use Pulmonale Hypertonie (DE-588)4176331-2 gnd |
| subject_GND | (DE-588)4176331-2 |
| title | Pulmonary hypertension pathophysiology, diagnosis, treatment, and development of a pulmonary selective therapy |
| title_alt | Pulmonale Hypertonie |
| title_auth | Pulmonary hypertension pathophysiology, diagnosis, treatment, and development of a pulmonary selective therapy |
| title_exact_search | Pulmonary hypertension pathophysiology, diagnosis, treatment, and development of a pulmonary selective therapy |
| title_exact_search_txtP | Pulmonary hypertension pathophysiology, diagnosis, treatment, and development of a pulmonary selective therapy |
| title_full | Pulmonary hypertension pathophysiology, diagnosis, treatment, and development of a pulmonary selective therapy Horst Olschewski ; Werner Seeger |
| title_fullStr | Pulmonary hypertension pathophysiology, diagnosis, treatment, and development of a pulmonary selective therapy Horst Olschewski ; Werner Seeger |
| title_full_unstemmed | Pulmonary hypertension pathophysiology, diagnosis, treatment, and development of a pulmonary selective therapy Horst Olschewski ; Werner Seeger |
| title_short | Pulmonary hypertension |
| title_sort | pulmonary hypertension pathophysiology diagnosis treatment and development of a pulmonary selective therapy |
| title_sub | pathophysiology, diagnosis, treatment, and development of a pulmonary selective therapy |
| topic | Hypertension, Pulmonary diagnosis Hypertension, Pulmonary physiopathology Hypertension, Pulmonary therapy Vasodilator Agents therapeutic use Pulmonale Hypertonie (DE-588)4176331-2 gnd |
| topic_facet | Hypertension, Pulmonary diagnosis Hypertension, Pulmonary physiopathology Hypertension, Pulmonary therapy Vasodilator Agents therapeutic use Pulmonale Hypertonie |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015404785&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT olschewskihorst pulmonalehypertonie AT seegerwerner pulmonalehypertonie AT olschewskihorst pulmonaryhypertensionpathophysiologydiagnosistreatmentanddevelopmentofapulmonaryselectivetherapy AT seegerwerner pulmonaryhypertensionpathophysiologydiagnosistreatmentanddevelopmentofapulmonaryselectivetherapy |